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Summary
Background High plasma HDL cholesterol is associated with reduced risk of myocardial infarction, but whether this 
association is causal is unclear. Exploiting the fact that genotypes are randomly assigned at meiosis, are independent 
of non-genetic confounding, and are unmodiﬁ ed by disease processes, mendelian random isation can be used to test 
the hypothesis that the association of a plasma biomarker with disease is causal.
Methods We performed two mendelian randomisation analyses. First, we used as an instrument a single nucleotide 
polymorphism (SNP) in the endothelial lipase gene (LIPG Asn396Ser) and tested this SNP in 20 studies 
(20 913 myocardial infarction cases, 95 407 controls). Second, we used as an instrument a genetic score consisting of 
14 common SNPs that exclusively associate with HDL cholesterol and tested this score in up to 12 482 cases of 
myocardial infarction and 41 331 controls. As a positive control, we also tested a genetic score of 13 common SNPs 
exclusively associated with LDL cholesterol.
Findings Carriers of the LIPG 396Ser allele (2·6% frequency) had higher HDL cholesterol (0·14 mmol/L higher, 
p=8×10–¹³) but similar levels of other lipid and non-lipid risk factors for myocardial infarction compared with non-
carriers. This diﬀ erence in HDL cholesterol is expected to decrease risk of myocardial infarction by 13% (odds ratio 
[OR] 0·87, 95% CI 0·84–0·91). However, we noted that the 396Ser allele was not associated with risk of myocardial 
infarction (OR 0·99, 95% CI 0·88–1·11, p=0·85). From observational epidemiology, an increase of 1 SD in HDL 
cholesterol was associated with reduced risk of myocardial infarction (OR 0·62, 95% CI 0·58–0·66). However, a 1 SD 
increase in HDL cholesterol due to genetic score was not associated with risk of myocardial infarction (OR 0·93, 
95% CI 0·68–1·26, p=0·63). For LDL cholesterol, the estimate from observational epidemiology (a 1 SD increase in 
LDL cholesterol associated with OR 1·54, 95% CI 1·45–1·63) was concordant with that from genetic score (OR 2·13, 
95% CI 1·69–2·69, p=2×10–¹⁰).
Interpretation Some genetic mechanisms that raise plasma HDL cholesterol do not seem to lower risk of myocardial 
infarction. These data challenge the concept that raising of plasma HDL cholesterol will uniformly translate into 
reductions in risk of myocardial infarction.
Funding US National Institutes of Health, The Wellcome Trust, European Union, British Heart Foundation, and the 
German Federal Ministry of Education and Research.
Introduction
Cholesterol fractions such as LDL and HDL cholesterol 
are among the most commonly measured biomarkers in 
clinical medicine.1 Observational studies have shown that 
LDL and HDL cholesterol have opposing associations 
with risk of myocardial infarction, with LDL cholesterol 
being positively associated and HDL cholesterol being 
inversely associated.2,3 However, observational studies 
cannot distinguish between a causal role in the 
pathological process and a marker of the underlying 
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patho physiology. These two possibilities can be distin-
guished in human beings by changes of the cholesterol 
fractions in large-scale randomised trials or by studies of 
inherited DNA variation. For LDL cholesterol, the results 
of both randomised trials of LDL-cholesterol-lowering 
treatments4 and from human mendelian diseases5,6 are 
concordant and suggest that plasma LDL cholesterol is 
causally related to risk of myocardial infarction. However, 
the available evidence for the causal relevance of HDL 
cholesterol from randomised trials or mendelian diseases 
is scarce and inconsistent.7,8
If a particular plasma biomarker is directly involved 
in an underlying pathological process, then inherited 
variation changing plasma concentrations of this bio-
marker should aﬀ ect risk of disease in the direction and 
magnitude predicted by the plasma concentrations. 
Referred to as mendelian randomisation,9–11 this ana-
lytical approach has been previously applied to plasma 
HDL cholesterol, albeit with restricted sample sizes, 
a small number of single nucleotide polymorphisms 
(SNPs) at a few genes, and with SNPs that aﬀ ect multiple 
lipid fractions.8,12–15 Hence, these studies have not been 
able to resolve fully the possible causal relevance of 
HDL cholesterol concentrations for risk of myocardial 
infarction.
Recently, we have used the genome-wide association 
approach to identify SNPs that aﬀ ect blood lipid con-
centrations.16,17 Additionally, through resequencing, we 
identiﬁ ed a loss-of-function coding SNP at the endothelial 
lipase gene (LIPG Asn396Ser) that aﬀ ects plasma HDL 
cholesterol in isolation.18,19 Here, we use these SNPs in 
case-control studies and prospective cohort studies to test 
the hypothesis that genetically raised plasma HDL 
cholesterol might be protective for myocardial infarction.
Methods
Study design
The study design consisted of two components. First, 
using a case-control design, we tested lipid-associated 
SNPs individually for association with risk of myocardial 
infarction. Second, using a mendelian randomisation 
design, we tested two instruments: (1) a single SNP that 
related exclusively to plasma HDL cholesterol (a loss-of-
function coding polymorphism at the endothelial lipase 
gene, LIPG Asn396Ser, rs61755018); and (2) a genetic 
score consisting of 14 common SNPs that exclusively 
associate with HDL cholesterol.
Study participants
Characteristics of cases of myocardial infarction and 
controls are shown in appendix p 19. Data for up to 
19 139 cases of myocardial infarction and 50 812 myo-
cardial-infarction-free controls were available from 
30 studies. Characteristics of the participants in six 
prospective cohort studies are shown in the appendix 
p 20. 50 763 participants from six cohort studies were 
studied and, of these, 4228 developed an incident fatal or 
non-fatal myocardial infarction. All participants were of 
self-reported European or South Asian ancestry.
Statistical analysis
In myocardial infarction cases and controls, we tested 
each of 25 SNPs for association with myocardial 
infarction in up to 30 studies. These 25 SNPs repre-
sented the initial polymorphisms mapped for plasma 
HDL or LDL cholesterol concentrations with a genome-
wide association approach.16 Each selected SNP has been 
associated with either HDL or LDL cholesterol at 
p<5×10–⁸. Genotyping details are provided in the appendix 
p 2. We undertook logistic regression with the outcome 
variable of myocardial infarction status, predictor variable 
of individual SNP genotype, and covariates of age, sex, 
and principal components of ancestry. We assumed a 
log-additive genetic model. Overall association for each 
SNP was evaluated with a ﬁ xed-eﬀ ects inverse-variance-
weighted meta-analysis.
Fatal or non-fatal myocardial infarction outcomes were 
ascertained in each of six prospective cohort studies as 
described in the appendix p 10. We constructed logistic 
regression models to examine the association of LIPG 
Asn396Ser genotype with myocardial infarction status, 
excluding participants who had had a previous myocardial 
infarc tion or ischaemic stroke. The predictor variable of 
LIPG Asn396Ser genotype was modelled in an additive 
model (ie, 0, 1, 2 copies of the 396Ser allele). Covariates in 
the model included age and sex. Overall association for 
each SNP was evaluated across the six studies with ﬁ xed-
eﬀ ects inverse-variance-weighted meta-analysis.
We estimated a predicted risk for LIPG Asn396Ser on 
the basis of the association of this SNP with plasma 
HDL cholesterol (appendix p 21) and the association of 
plasma HDL cholesterol with myocardial infarction 
(appendix p 22) in the population. Details are provided in 
the appendix p 2.
We undertook instrumental variable analysis using 
LIPG Asn396Ser in six prospective cohort studies as 
listed in the appendix p 23. We additionally did an 
instrumental variable analysis using multiple genetic 
variants as instruments.20 Details of the instrumental 
variable analysis methods are provided in the appendix 
p 4. We regarded a two-tailed p<0·05 as nominally 
signiﬁ cant. Heterogeneity statistics were calculated as 
described.21 SAS version 9.1, the R package, STATA, or 
PLINK software were used for all statistical analyses.22
Role of the funding source
The sponsors had no role in the conduct or interpretation 
of the study. The corresponding author had full access to 
all data in the study and had ﬁ nal responsibility for the 
decision to submit for publication.
Results
To validate the statistical framework and clinical samples, 
we ﬁ rst tested SNPs related to plasma LDL cholesterol in 
See Online for appendix
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case-control studies (table 1). For nine of ten SNPs 
associated with LDL cholesterol, the allele correlated with 
increased LDL cholesterol was also associated with 
increased risk of myocardial infarction (p<0·05; table 1).
Having established that SNPs related to plasma LDL 
cholesterol consistently aﬀ ected risk of myocardial 
infarction, we applied the same methodological frame-
work in the same samples to test the hypothesis that 
genetic modulation of HDL cholesterol would aﬀ ect risk 
of myocardial infarction. Of 15 loci related to plasma 
HDL cholesterol, at six loci (LPL, TRIB1, APOA1-APOC3-
APOA4-APOA5 cluster, CETP, ANGPTL4, and GALNT2) 
Chromosome Gene(s) of interest within 
or near associated interval
Major allele, 
minor allele 
(minor allele 
frequency)*
Modelled 
allele
Eﬀ ect of 
modelled 
allele on 
plasma 
LDL 
cholesterol 
(mmol/L)*
Eﬀ ect of 
modelled 
allele on 
plasma 
HDL 
cholesterol 
(mmol/L)*
Eﬀ ect of 
modelled 
allele on 
plasma 
triglycerides 
(mmol/L)*
Sample size 
(MI cases/
MI-free 
controls)
For modelled 
allele, observed 
change in MI risk 
(%; 95% CI)
For 
modelled 
allele, 
p value for 
association 
with MI
rs646776 1p13 CELSR2, PSRC1, SORT1† T, C (0·21) T 0·20 –0·03 ·· 19 139/50 812 16% (12–19) 4×10¹⁶†
rs6511720 19p13 LDLR† G, T (0·10) G 0·23 ·· 0·09 16 503/46 576 23% (17–30) 4×10¹²†
rs11206510 1p32 PCSK9† T, C (0·17) T 0·05 ·· ·· 18 455/23 075 13% (9–16) 1×10⁹†
rs3798220 6q25 LPA† T, C (0·02) C 0·36‡ ·· ·· 6658/5823 72% (39–211) 4×10⁷†
rs562338 2p24 APOB† G, A (0·20) G 0·14 ·· ·· 19 139/50 812 8% (4–12) 5×10⁵†
rs6544713 2p21 ABCG8† C, T (0·32) T 0·13 ·· ·· 14 818/45 454 8% (4–11) 5×10⁵†
rs7953249 12q24 HNF1A† A, G (0·44) G 0·07 ·· ·· 19 139/50 812 5% (3–9) 2×10⁴†
rs10402271 19q13 APOE-APOC1-APOC4-APOC2† T, G (0·33) G 0·12 ·· ·· 19 139/50 812 4% (1–7) 0·007†
rs3846663 5q13 HMGCR† C, T (0·38) T 0·06 ·· ·· 19 139/50 812 4% (1–7) 0·01†
rs1501908 5q23 TIMD4-HAVCR1 C, G (0·37) C 0·06 ·· ·· 18 310/49 897 3% (0–6) 0·08
*Data presented from a meta-analysis of seven cohorts (n up to 19 840) as presented in reference 16; the eﬀ ect of each SNP on a lipid trait was modelled if the association of the SNP with a plasma lipid trait 
exceeded nominal signiﬁ cance (p<0·05). †Loci and SNPs that exceeded nominal signiﬁ cance (p<0·05) for association of modelled allele with MI; all modelled alleles increased LDL cholesterol. ‡The C allele at this 
LPA variant is related to increased plasma lipoprotein(a) as presented in reference 16.
Table 1: Association of myocardial infarction (MI) with single nucleotide polymorphisms (SNPs) previously found to relate to plasma LDL cholesterol
Chromosome Gene(s) of interest within 
or near associated interval
Major 
allele, 
minor allele 
(minor 
allele 
frequency)*
Modelled 
allele
Eﬀ ect of 
modelled 
allele on 
plasma 
HDL 
cholesterol 
(mmol/L)*
Eﬀ ect of 
modelled 
allele on 
plasma 
triglycerides 
(mmol/L)*
Eﬀ ect of 
modelled 
allele on 
plasma 
LDL 
cholesterol 
(mmol/L)*
Sample size 
(MI cases/
MI-free 
controls)
For modelled 
allele, observed 
change in MI 
risk (%; 95% CI)
For 
modelled 
allele, 
p value for 
association 
with MI
rs17482753 8p21 LPL† G, T (0·10) T 0·08 –0·24 ·· 19 139/50 812 –12% (–16 to –7) 4×10⁷†
rs17321515 8q24 TRIB1† A, G (0·45) G 0·02 –0·11 –0·05 19 139/50 812 –7% (–9 to –4) 2×10⁶†
rs6589566 11q23 APOA1-APOC3-APOA4-APOA5† A, G (0·07) A 0·05 –0·27 –0·09 18 310/49 897 –10% (–15 to –5) 8×10⁵†
rs4846914 1q42 GALNT2† A, G (0·40) A 0·02 –0·03 ·· 19 139/50 812 –3% (–6 to –1) 0·02†
rs2967605 19p13 ANGPTL4† C, T (0·16) C 0·05 –0·07 ·· 13 595/16 423 –5% (–10 to –1) 0·03†
rs3764261 16q13 CETP† C, A (0·32) A 0·10 ·· –0·03 16 503/46 576 –4% (–7 to 0) 0·04†
rs61755018 
(Asn396Ser)
18q21 LIPG A, G (0·015) G 0·14‡ ·· ·· 17 165/49 077 –6% (–18 to 9) 0·41
rs17145738 7q11 MLXIPL C, T (0·11) T 0·03 –0·15 ·· 19 139/50 812 –1% (–4 to 3) 0·61
rs3890182 9q31 ABCA1 G, A (0·14) G 0·03 ·· 0·05 19 139/50 812 –1% (–5 to 4) 0·76
rs2338104 12q24 MMAB, MVK G, C (0·46) G 0·03 ·· ·· 19 139/50 812 0% (–3 to 3) 0·85
rs471364 9p22 TTC39B T, C (0·12) T 0·03 ·· ·· 15 693/47 098 0% (–5 to 5) 0·97
rs2271293 16q22 LCAT G, A (0·11) A 0·03 ·· ·· 19 139/50 812 4% (–1 to 8) 0·10
rs174547 11q12 FADS1-FADS2-FADS3 T, C (0·33) T 0·03 –0·06 ·· 19 139/50 812 3% (–1 to 6) 0·11
rs1800588 15q22 LIPC C, T (0·22) T 0·05 0·07 ·· 17 917/49 514 4% (0 to 7) 0·04
rs16988929 20q13 HNF4A C, T (0·01) T 0·01 ·· ·· 17 041/20 137 31% (12 to 54) 9×10⁴
*Data presented from a meta-analysis of seven cohorts (n up to 19 840) as presented in reference 16; the eﬀ ect of each SNP on a lipid trait was modelled if the association of the SNP with a plasma lipid trait 
exceeded nominal signiﬁ cance (p<0·05). †Loci and SNPs that exceeded nominal signiﬁ cance (p<0·05) for association of modelled allele with MI; all modelled alleles increased HDL cholesterol. ‡Eﬀ ect size 
presented is from the Atherosclerosis Risk in Communities Study.
Table 2: Association of myocardial infarction (MI) with single nucleotide polymorphisms (SNPs) previously found to relate to plasma HDL cholesterol
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the allele correlated with raised HDL cholesterol was also 
associated with decreased risk of myocardial infarction 
(p<0·05; table 2). Of note, at the HNF4A locus, the HDL-
cholesterol-raising allele was surprisingly associated with 
increased risk of myocardial infarction (p=0·0009).
All six SNPs associated with both HDL cholesterol and 
myocardial infarction had additional eﬀ ects on plasma 
LDL cholesterol or triglycerides, or both (p<5×10–⁸ for the 
additional eﬀ ects on LDL cholesterol or triglycer ides). 
For example, at APOA1-APOC3-APOA4-APOA5 
rs6589566, the allele associated with increased HDL 
cholesterol also relates to reduced LDL cholesterol and 
reduced triglycerides. The pleiotropic eﬀ ects of such 
SNPs undermine the ability to deﬁ ne a causal role for 
HDL cholesterol, independent of eﬀ ects on LDL 
cholesterol or triglycerides.
To evaluate plasma HDL cholesterol speciﬁ cally, 
we undertook mendelian randomisation, a form of 
instrumental variable analysis.23 We identiﬁ ed a variant 
that aﬀ ected only plasma HDL cholesterol without 
changing other lipid or non-lipid cardiovascular risk 
factors. In the LIPG gene, roughly 2·6% of individuals 
carry a serine substitution at aminoacid 396 (substituted 
for wild-type asparagine). Carrier status for 396Ser was 
associated with signiﬁ cant increases in HDL cholesterol 
in each of four prospective cohort studies, with the eﬀ ect 
size ranging from 0·08 mmol/L to 0·28 mmol/L per 
copy of the Ser allele (ﬁ gure 1, appendix p 21; p=0·002 in 
FHS, p=0·02 in CCHS, p=5×10–⁶ in MDC, and p=7×10–⁷ 
in ARIC).
In a meta-analysis including all four studies, carrier 
status for 396Ser was associated with an increase of 
roughly 0·29 SD units in HDL cholesterol (p=8×10–¹³). 
There was no evidence of heterogeneity across the four 
studies (I²=0·58; Cochran’s heterogeneity p=0·07). LIPG 
Asn396Ser was not signiﬁ cantly associated with other 
risk factors for myocardial infarction including plasma 
LDL cholesterol, triglycerides, systolic blood pressure, 
body-mass index, risk of type 2 diabetes, fasting glucose, 
plasma C-reactive protein, waist-to-hip ratio, ﬁ brinogen, 
and small LDL particle concentration (p>0·05 for each; 
appendix pp 24–26). Therefore, LIPG Asn396Ser 
satisﬁ ed the three main criteria for mendelian 
randomisation analysis—ie, that the genotype should be 
associated with an intermediate biomarker (ﬁ gure 1), 
should not be associated with confounding factors 
(appendix pp 24–46), and should exert its eﬀ ect on the 
clinical outcome only through the speciﬁ c intermediate 
biomarker (appendix p 22).24
Under the model that plasma HDL cholesterol causally 
relates to risk of myocardial infarction, individuals with 
an inherited increase in HDL cholesterol (eg, those 
carrying the LIPG 396Ser allele) are expected to have 
reduced risk of myocardial infarction. On the basis of the 
associations between SNPs and HDL cholesterol, and 
HDL cholesterol and myocardial infarction, we estimated 
that carriage of LIPG 396Ser should decrease risk of 
myocardial infarction by 13% (odds ratio [OR] 0·87, 
95% CI 0·84–0·91).
To establish whether LIPG 396Ser carriers are indeed 
protected from risk of myocardial infarction, we studied 
the association of LIPG Asn396Ser with incident 
myocardial infarction in 50 763 participants from six 
prospective cohort studies, the gold standard with respect 
to epidemiological study design. Of these participants, 
4228 developed a ﬁ rst myocardial infarction event. LIPG 
Asn396Ser was not associated with myocardial infarction 
in any of the six studies (ﬁ gure 2). Combining these 
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Figure 1: Plasma HDL cholesterol concentrations in carriers versus non-carriers of the Ser allele at the 
LIPG Asn396Ser polymorphism
Error bars show standard error. FHS=Framingham Heart Study. CCHS=Copenhagen City Heart Study. MDC=Malmo 
Diet and Cancer Study. ARIC=Atherosclerosis Risk in Communities Study.
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Figure 2: Association of LIPG Asn396Ser with myocardial infarction in 116 320 participants from 20 studies
In each study, the HDL-cholesterol-raising serine allele was modelled.
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studies in a meta-analysis, LIPG Asn396Ser allele was 
not associated with myocardial infarction (OR 1·10, 
95% CI 0·89–1·37, p=0·37; ﬁ gure 2). There was no 
evidence for heterogeneity across the six cohorts (I²=0·17; 
Cochran’s heterogeneity p=0·31).
We also studied LIPG Asn396Ser in case-control 
studies involving an additional 16 685 cases of myocardial 
infarction and 48 872 controls and noted that this SNP 
was not associated with myocardial infarction (OR 0·94, 
95% CI 0·82–1·09, p=0·41; table 2, ﬁ gure 2), with no 
evidence of heterogeneity across the 14 case-control 
studies (I²=0·34; Cochran’s heterogeneity p=0·11). 
Finally, we used meta-analysis to combine the evidence 
from both the prospective studies and case-control 
studies (116 320 participants; 20 913 cases and 95 407 con-
trols). In all available samples, LIPG Asn396Ser 
remained not associated with risk of myocardial 
infarction (OR 0·99, 95% CI 0·88–1·11, p=0·85; 
ﬁ gure 2). There was no evidence for heterogeneity across 
all 20 studies (I²=0·30; Cochran’s heterogeneity p=0·10).
We formally estimated the magnitude of an association 
of genetically raised HDL cholesterol with myocardial 
infarction, using LIPG Asn396Ser as the instrument. 
The mendelian randomisation estimate was computed 
from the ratio of the coeﬃ  cient of the association 
between genotype and disease to that of the association 
between genotype and plasma HDL cholesterol; this 
instrumental variable estimate reﬂ ects the potential 
causal eﬀ ect of plasma HDL cholesterol on the risk of 
myocardial infarction.
Table 3 presents the instrumental variable estimate for 
the association of plasma HDL cholesterol with risk of 
myocardial infarction in each of six prospective cohort 
studies. In each study, genetically raised plasma HDL 
cholesterol was not associated with risk of myocardial 
infarction. In meta-analysis, genetically raised plasma 
HDL cholesterol was also not associated with risk of 
myocardial infarction (OR 1·02 per 0·03 mmol/L 
[1 mg/dL] increase in HDL cholesterol, 95% CI 
0·95–1·09, p=0·64; OR 1·28 per 0·39 mmol/L [15 mg/dL] 
increase in HDL cholesterol, 95% CI 0·46–3·61, p=0·64).
Statistical power for instrumental variable analysis 
could be increased if multiple genetic variants in 
combination are used as instruments, according to a 
recent proposal.20 From our genome-wide association 
study of plasma lipid traits involving more than 
100 000 individuals,17 we noted that 13 common SNPs 
had statistical evidence at genome-wide levels of 
signiﬁ cance (p<5×10–⁸) for plasma LDL cholesterol and 
no evidence for association with triglycerides (p>0·01) 
or HDL cholesterol (p>0·01). We constructed a genetic 
score for LDL cholesterol combining the LDL-
cholesterol-raising alleles at each of these 13 SNPs 
(appendix p 27).25 We also noted that 14 common SNPs 
had statistical evidence at genome-wide levels of 
signiﬁ cance (p<5×10–⁸) for plasma HDL cholesterol and 
no evidence for association with triglycerides (p>0·01) 
or LDL cholesterol (p>0·01). We constructed a genetic 
score for HDL cholesterol combining the HDL-
cholesterol-raising alleles at each of these 14 SNPs 
(appendix p 28). Each SNP was given a weight based on 
the degree of change in LDL or HDL cholesterol as 
estimated in roughly 100 000 individuals.17
We tested the association of genetic scores for LDL 
and HDL cholesterol separately for association with 
myocardial infarction in up to 53 146 cases and controls 
from the CARDIoGRAM study.26 From observational 
epidemiology, an increase of 1 SD in usual LDL 
cholesterol was associated with raised risk of myocardial 
infarction (OR 1·54, 95% CI 1·45–1·63; appendix p 22). 
In a mendelian randomisation analysis, a 1 SD increase 
in LDL cholesterol due to genetic score was also 
associated with risk of myocardial infarction (OR 2·13, 
95% CI 1·69–2·69, p=2×10–¹⁰; table 4). From observational 
epidemiology, a 1 SD rise in usual HDL cholesterol was 
associated with lowered risk of myocardial infarction 
Observational epidemiology Genetically raised
Odds ratio (95% CI) per 
0·03 mmol/L (1 mg/dL) increase 
in plasma HDL cholesterol
p value Odds ratio (95% CI) per 
0·03 mmol/L (1 mg/dL) increase 
in plasma HDL cholesterol
p value
Cohort
Atherosclerosis Risk in Communities Study 0·97 (0·96–0·98) 7×10¹⁸ 0·96 (0·86–1·07) 0·44
Copenhagen City Heart Study 0·98 (0·98–0·99) 6×10¹³ 1·09 (0·95–1·26) 0·21
Malmo Diet and Cancer Study, Cardiovascular Cohort 0·97 (0·96–0·98) 1×10⁶ 0·82 (0·66–1·01) 0·06
Framingham Heart Study 0·96 (0·94–0·98) 4×10⁶ 1·17 (1·00–1·37) 0·06
Health Professionals Follow-up Study ·· ·· 1·84 (0·39–8·62) 0·16
Danish Diet, Cancer, and Health Study ·· ·· 1·05 (0·79–1·41) 0·71
Meta-analysis of cohort studies
Per 0·03 mmol/L (1 mg/dL) increase in plasma HDL cholesterol 0·98 (0·97–0·98) 4×10³⁶ 1·02 (0·95–1·09) 0·64
Per 0·39 mmol/L (15 mg/dL) increase in plasma HDL cholesterol 0·70 (0·66–0·74) 4×10³⁶ 1·28 (0·46–3·61) 0·64
Table 3: Instrumental variable analysis estimate of the association of genetically raised HDL cholesterol and risk of myocardial infarction using 
LIPG Asn396Ser as an instrument
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(OR 0·62, 95% CI 0·58–0·66; appendix p 22). However, 
in mendelian randomisation analysis, a 1 SD increase in 
HDL cholesterol due to genetic score was not associated 
with risk of myocardial infarction (OR 0·93, 95% CI 
0·68–1·26, p=0·63; table 4).
Discussion
For a biomarker directly involved in disease patho genesis, 
we expect a genetic variant that modulates the biomarker 
to likewise confer risk of disease. We tested this 
hypothesis for two plasma biomarkers: LDL and HDL 
cholesterol. SNPs aﬀ ecting LDL cholesterol were 
consistently related to risk of myocardial infarction. 
However, we unexpectedly found that LIPG Asn396Ser, a 
genetic variant that speciﬁ cally and substantially increases 
plasma HDL cholesterol, did not reduce risk of myocardial 
infarction. A genetic score combining 14 variants 
exclusively related to HDL cholesterol also showed no 
association with risk of myocardial infarction (panel).
These results challenge several established views 
about plasma HDL cholesterol. First, these data 
question the concept that raising of plasma HDL 
cholesterol should uniformly translate into reductions 
in risk of myocardial infarction. We raise the strong 
possibility that a speciﬁ c means of raising of HDL 
cholesterol in human beings—namely, inhibition of 
endothelial lipase—will not reduce risk of myocardial 
infarction. In animal models, inhib ition or deletion of 
the endothelial lipase gene increases HDL cholesterol 
concentrations,27 but there has been debate as to the 
consequent eﬀ ect on atherosclerosis. One report 
suggested that mice deleted for Lipg on an Apoe 
knockout genetic background have decreased aortic 
atherosclerosis,28 but a subsequent study showed no 
eﬀ ect of Lipg deletion on aortic atherosclerosis.29
Second, these ﬁ ndings emphasise the potential limi-
tation of plasma HDL cholesterol as a surrogate measure 
for risk of myocardial infarction in intervention trials. 
The data presented here using mendelian randomisation 
are consistent with results from completed random-
ised controlled trials focused on raising plasma HDL 
cholesterol. Hormone replacement therapy raised 
plasma HDL cholesterol but did not lower risk of 
myocardial infarction.30 In the Atherothrombosis 
Inter vention in Metabolic Syndrome with Low HDL 
Cholesterol/High Triglyceride and Impact on Global 
Health Outcomes (AIM-HIGH) trial,31 the addition of 
long-acting niacin to background simvastatin increased 
HDL cholesterol and lowered triglycerides but did not 
lower risk of cardio vascular events.
Of note, at the cholesterol ester transfer protein (CETP) 
gene, we did ﬁ nd that common genetic variation reduces 
risk of myocardial infarction by 4%, a result in line 
with an earlier meta-analysis.32 However, the CETP 
variant both increases HDL cholesterol and lowers LDL 
cholesterol17 in a manner similar to pharmacological 
inhibitors of CETP.33 As such, whether the protection 
aﬀ orded by the CETP variant is due to the change in 
HDL or LDL cholesterol is diﬃ  cult to distinguish.
Third, biomarkers that assay HDL function might 
overcome some limitations of standard HDL cholesterol 
assays. However, a challenge will remain—namely, to 
prove that new functional HDL biomarkers reﬂ ect a 
causal association with myocardial infarction rather 
than an indirect one, as seems to be the case with 
plasma HDL cholesterol. For example, using a new 
in-vitro measure involving mouse macrophages and 
human serum, Khera and colleagues34 showed an 
inverse correlation between a speciﬁ c functional 
property of HDL, cholesterol eﬄ  ux capacity, and coro-
nary artery disease status. The present study suggests 
that a fruitful approach to the causal evaluation of such 
Odds ratio (95% CI) 
per SD increase in 
plasma lipid based 
on observational 
epidemiology*
Odds ratio (95% CI) per SD 
increase in plasma lipid 
conferred by genetic score†
LDL cholesterol 1·54 (1·45–1·63) 2·13 (1·69–2·69), p=2×10¹⁰
HDL cholesterol 0·62 (0·58–0·66) 0·93 (0·68–1·26), p=0·63
*Observational epidemiology estimates derived from more than 25 000 individuals 
from prospective cohort studies as shown in the appendix p 22. †LDL genetic score 
consisting of 13 single nucleotide polymorphisms (SNPs) as shown in the appendix 
p 27; HDL genetic score consisting of 14 SNPs as shown in the appendix p 28.
Table 4: Estimate of the association of genetically raised LDL cholesterol 
or HDL cholesterol and risk of myocardial infarction using multiple 
genetic variants as instruments
Panel: Research in context
Systematic review
Electronic searches of Medline and PubMed, supplemented by 
hand searches of reference lists of other review articles, 
identiﬁ ed reports from three large mendelian randomisation 
studies for plasma HDL cholesterol.7,12,15 In each of these 
previous reports, genetically increased plasma HDL cholesterol 
was not associated with risk of ischaemic heart disease.
Interpretation
The present study tested a naturally occurring loss-of-
function variant in the endothelial lipase gene and, with this 
new instrument, we conﬁ rm that genetically raised plasma 
HDL cholesterol is not associated with risk of myocardial 
infarction. The study further extends previous work by testing 
an instrument consisting of 14 common variants exclusively 
associated with plasma HDL cholesterol. A genetic score 
consisting of these 14 variants was not associated with risk of 
myocardial infarction. These results show that some ways of 
raising HDL cholesterol might not reduce risk of myocardial 
infarction in human beings. Therefore, if an intervention such 
as a drug raises HDL cholesterol, we cannot automatically 
assume that risk of myocardial infarction will be reduced.
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functional measures in human beings might be large-
scale study of relevant inherited DNA variation of HDL 
function.
There are inherent limitations to the mendelian ran-
domisation study design. Naturally occurring genetic 
variation could be a useful instrument to assess causality 
provided that several requirements have been satisﬁ ed.35,36 
First, one needs suitable genetic variants for the study of 
the modiﬁ able exposure of interest (in our case, plasma 
HDL cholesterol). Although many loci are associated 
with plasma HDL cholesterol, we found LIPG Asn396Ser 
to be particularly informative because it is speciﬁ cally 
associated with substantial increases in HDL cholesterol. 
Additionally, we evaluated a set of 14 common genetic 
variants that also exclusively aﬀ ected HDL cholesterol. 
Both instruments, LIPG Asn396Ser and the genetic 
score, produced similar results.
Second, reliable genotype-to-intermediate-phenotype 
and intermediate-phenotype-to-disease eﬀ ect estimates 
are needed. To obtain as precise estimates as possible, we 
derived SNP-to-lipid eﬀ ect estimates from analysis of a 
large sample involving more than 24 000 participants. 
Estimates of plasma lipid to myocardial infarction were 
derived from meta-analysis of four large cohort studies 
involving more than 25 000 participants.
Third, there must not be pleiotropic eﬀ ects of 
the genetic variants of interest. We cannot exclude all 
potential pleiotropic eﬀ ects of the LIPG Asn396Ser SNP; 
however, we have assessed but did not detect pleiotropic 
eﬀ ects on other cardiovascular risk factors including 
LDL cholesterol, small LDL particle concentration, tri-
glycerides, body-mass index, systolic blood pressure, 
plasma C-reactive protein, and type 2 diabetes status.
Finally, the absence of association of individual SNPs 
with myocardial infarction could be due to low statistical 
power. However, for the crucial SNP in the mendelian 
randomisation study for plasma HDL cholesterol, we 
had suﬃ  cient power. In this study, LIPG Asn396Ser has 
been tested in 20 913 myocardial infarction cases and 
95 407 myocardial-infarction-free participants. We had 
90% power to detect the expected 13% reduction in risk 
of myocardial infarction for the LIPG Asn396Ser variant 
(at a two-sided α of 0·05).
In summary, our results showed that polymorphisms 
related to plasma LDL cholesterol were consistently 
associated with risk of myocardial infarction, whereas 
this was not the case for variants related to plasma HDL 
cholesterol. A polymorphism in the endothelial lipase 
gene and a genetic score of 14 common SNPs that 
speciﬁ cally raised HDL cholesterol were not associated 
with myocardial infarction, suggesting that some 
genetic mechanisms that raise HDL cholesterol do not 
lower risk of myocardial infarction. Hence, inter-
ventions (lifestyle or pharmacological) that raise plasma 
HDL cholesterol cannot be assumed ipso facto to lead 
to a corresponding beneﬁ t with respect to risk of 
myocardial infarction.
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